High-Risk Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy versus Transarterial Chemoembolization
DOI: https://doi.org/10.2147/jhc.s455953
2024-03-27
Journal of Hepatocellular Carcinoma
Abstract:Baogen Zhang, 1, &ast Biqing Huang, 2, &ast Fan Yang, 3, &ast Jiandong Yang, 1 Man Kong, 1 Jing Wang, 1 Yaoxian Xiang, 1 Kangjie Wang, 1 Ruchen Peng, 4 Kun Yang, 4 Chao An, 5 Dong Yan 1 1 Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149, People's Republic of China; 2 Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, People's Republic of China; 3 Department of Cardiology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, People's Republic of China; 4 Department of Medical Imaging, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149, People's Republic of China; 5 Department of Minimal Invasive Intervention, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative, Innovation Center for Cancer Medicine, Guangzhou, 510060, People's Republic of China &astThese authors contributed equally to this work Correspondence: Dong Yan, Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149, People's Republic of China, Tel/Fax +86-10-69543901, Email Chao An, Department of Minimal invasive intervention, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative, Innovation Center for Cancer Medicine, Guangzhou, 510060, People's Republic of China, Tel/Fax +86-20-87343272, Email Objective: To compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) with transarterial chemoembolization (TACE) for the treatment of high-risk hepatocellular carcinoma (hHCC) patients. Methods: Between January 2014 and August 2022, a total of 1765 consecutive patients with hHCC who underwent initial intra-arterial therapies were reviewed and divided into a TACE group (n, 507) and a HAIC group (n, 426). The study used propensity score matching (PSM) to reduce selectivity bias. Overall survival (OS) and progression-free survival (PFS) were compared using Kaplan‒Meier curves with the Log rank test. The objective response rate (ORR), conversion surgery rate (CSR) adverse event (AE) comparison and subgroup analysis were performed between the two groups. Results: After PSM 1:1, 444 patients were divided into two groups. The patients with hHCC who received HAIC had higher median PFS (6.1 vs 3.3 months, P < 0.001) and OS (10.3 vs 8.2 months, P =0.303) than TACE. Higher ORR (24.8% vs 11.7%) and CSR (15.5% vs 8.9%) were found in the HAIC group than in the TACE group (both P < 0.05). The incidence of grade 3/4 AE was 23.9% and 8.1% in the TACE and HAIC groups, respectively. The subgroup analysis suggest that HAIC appeared to particularly benefit patients with tumor diameter of more than 10 centimeters (hazard ratio [HR], 0.6; 95% CI, 0.47– 0.77; p, 0.00) and PVTT Vp4 (HR, 0.56; 95% CI, 0.39– 0.8; P , 0.01) for PFS outperforming TACE. Conclusion: HAIC can provide better disease control for hHCC than cTACE, with a comparable long-term OS and safety. Keywords: hepatocellular carcinoma, transarterial chemoembolization, hepatic artery infusion chemotherapy, high risk Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related mortality worldwide, 1 and a large proportion of patients are in advanced stages at the time of diagnosis, with a poor prognosis, especially for patients with the combination of portal vein tumor thrombosis (PVTT), 2–4 bile duct invasion or large HCC with high tumor burden. 5 Previously, the IMbrave150 study defined combined Vp4 portal vein embolization, bile duct invasion, and tumor infiltration volume of more than 50% as high risk, 6 but significant challenges remain in the treatment of these populations. Transarterial chemoembolization (TACE) is recommended for the treatment of advanced HCC according to the National Comprehensive Cancer Network (NCCN) and China Liver Cancer Staging (CNLC) guidelines, including the BRIDGE study, which showed that TACE is a commonly used therapy for the treatment of advanced HCC. 7 However, the Barcelona Clinic Liver Cancer (BCLC) staged treatment algorithm endorsed by the American Association for the Study of Liver Diseases (ASLD) and the European Association for the Study of the Liver (EASL) do not recommend TACE for patients with PVTT. 5,8 VP4 in particular remains a relative contraindication to TACE due to the pot -Abstract Truncated-
oncology